Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study

Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study

Publication: J Pharmacokinet Pharmacodyn
Software: GastroPlus®
Division: PBPK

A physiologically based model describing the dissolution, diffusion, and transfer of drug from the intra-articular (IA) space to the plasma, was developed for GastroPlus v9.8.

The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development

The emerging role of physiologically-based pharmacokinetic/biopharmaceutics modeling in formulation development

Publication: Arch Pharm
Software: GastroPlus®

Computer-based (in silico) modeling & simulation tools have been embraced in different fields of pharmaceutics for a variety of applications.

Pharmacokinetics of tulathromycin in pregnant ewes (Ovis aries) challenged with Campylobacter jejuni

Pharmacokinetics of tulathromycin in pregnant ewes (Ovis aries) challenged with Campylobacter jejuni

Publication: PLoS One
Software: PKanalix®

The purpose of this study was to evaluate the pharmacokinetics of tulathromycin in the plasma and maternal and fetal tissues of pregnant ewes when administered within 24 hours of a...

PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-Glucuronosyltransferase Substrates

PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-Glucuronosyltransferase Substrates

Publication: Pharmaceutics
Division: PBPK

Uridine 5′-diphospho-glucuronosyltransferases (UGTs) are expressed in the small intestines, but prediction of first-pass extraction from the related metabolism is not well studied.

Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity

Quantitative Systems Toxicology Modeling Predicts that Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity

Publication: Clinical Pharmacology & Therapeutics
Software: DILIsym®

Patients with autosomal dominant polycystic kidney disease (ADPKD) exhibit enhanced susceptibility to tolvaptan hepatotoxicity relative to other patient populations.

Computational pharmaceutics – A new paradigm of drug delivery

Computational pharmaceutics – A new paradigm of drug delivery

Authors: Wang W, Ye Z, Gao H, Ouyang D
Publication: J Control Release
Software: GastroPlus®

In recent decades pharmaceutics and drug delivery have become increasingly critical in the pharmaceutical industry due to longer time, higher cost, and less productivity of new molecular entities (NMEs).

In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets

In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets

Publication: Pharmaceutics
Software: GastroPlus®

Amorphous solid dispersion (ASD) dosage forms can improve the oral bioavailability of poorly water-soluble drugs, enabling the commercialization of new chemical entities and improving the efficacy and patient...

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

Publication: EClinicalMedicine
Software: PKanalix®

IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes.

Machine Learning in Drug Discovery: A Review

Machine Learning in Drug Discovery: A Review

Publication: Art. Intel. Review
Software: ADMET Predictor®

This review provides the feasible literature on drug discovery through ML tools and techniques that are enforced in every phase of drug development to accelerate the research....

Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis

Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis

Publication: Clinical Drug Investigation

Daridorexant is a new dual orexin receptor antagonist currently in late-stage clinical development for the treatment of insomnia.

Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development

Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development

Publication: AAPS PharmSciTech
Software: GastroPlus®

Pediatric drug development faces many difficulties. Traditionally, pediatric drug doses are simply calculated linearly based on the body weight, age, and body surface area of adults.

Multitask machine learning models for predicting lipophilicity (logP) in the SAMPL7 challenge

Multitask machine learning models for predicting lipophilicity (logP) in the SAMPL7 challenge

Publication: J Comput Aided Mol Des
Software: ADMET Predictor®

Accurate prediction of lipophilicity—logP—based on molecular structures is a well-established field. Predictions of logP are often used to drive forward drug discovery projects.

Development of rivaroxaban microemulsion-based hydrogel for transdermal treatment and prevention of venous thromboembolism

Development of rivaroxaban microemulsion-based hydrogel for transdermal treatment and prevention of venous thromboembolism

Publication: Colloids Surf B Biointerfaces
Software: GastroPlus®

We have developed a microemulsion (ME)-based hydrogel, containing propylene glycol, Azone®, Labrasol®, isobutanol and water (20:3:18:3:56), for the transdermal delivery of rivaroxaban (RVX). Formulation ME-1:RVX...

An insight into the anticancer potential of carbamates and thiocarbamates of 10-demethoxy-10-methylaminocolchicine

An insight into the anticancer potential of carbamates and thiocarbamates of 10-demethoxy-10-methylaminocolchicine

Publication: Eur J Med Chem
Software: ADMET Predictor®

Colchicine shows very high antimitotic activity, therefore, it is used as a lead compound for generation of new anticancer agents. In the hope of developing novel, useful drugs with more favourable pharmacological...

Cosmetics Europe evaluation of 6 in silico skin penetration models

Cosmetics Europe evaluation of 6 in silico skin penetration models

Publication: Computational Toxicology
Software: GastroPlus®

The ADME TF aims to develop in silico skin penetration models using in vitro human skin penetration data for 25 chemicals solubilized in water.